![]() |
|
|
A more recent version of this article appeared on September 1, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 28, 2008
Revised on June 20, 2008
Accepted on June 29, 2008
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255
Monitoring Editor: John L. Cleveland
The cellular activity of Yondelis® (Trabectedin, Ecteinascidin 743, Et743) is known to depend on transcription-coupled-nucleotide excision repair (TCR). However, the subsequent cellular effects of Et743 are not fully understood. Here we show that Et743 induces both transcription- and replication-coupled DNA double-strand breaks (DSBs) that are detectible by neutral COMET assay and as
-H2AX foci that colocalize with 53BP1, Mre11, Ser1981-pATM, and Thr68-pChk2. The transcription coupled-DSBs (TC-DSBs) induced by Et743 depended both on TCR and Mre11-Rad50-Nbs1 (MRN) and were associated with DNA-PK-dependent
-H2AX foci. In contrast to DNA-PK, ATM phosphorylated H2AX both in NER-proficient and –deficient cells, but its full activation was dependent on H2AX as well as DNA-PK, suggesting a positive feedback loop: DNA-PK-
-H2AX-ATM. Knocking-out H2AX or inactivating DNA-PK reduced Et743s antiproliferative activity while ATM and MRN tended to act as survival factors. Our results highlight the interplays between ATM and DNA-PK, and their impacts on H2AX phosphorylation and cell survival. They also suggest that
-H2AX may serve as a biomarker in patients treated with Et743 and that molecular profiling of tumors for TCR, MRN, ATM, and DNA-PK might be useful to anticipate tumor response to Et743 treatment.
This article has been cited by other articles:
![]() |
L. H. Wang, T. D. Pfister, R. E. Parchment, S. Kummar, L. Rubinstein, Y. A. Evrard, M. E. Gutierrez, A. J. Murgo, J. E. Tomaszewski, J. H. Doroshow, et al. Monitoring Drug-Induced {gamma}H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells Clin. Cancer Res., February 1, 2010; 16(3): 1073 - 1084. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guirouilh-Barbat, S. Antony, and Y. Pommier Zalypsis (PM00104) is a potent inducer of {gamma}-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition Mol. Cancer Ther., July 1, 2009; 8(7): 2007 - 2014. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guirouilh-Barbat, Y.-W. Zhang, and Y. Pommier Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin Mol. Cancer Ther., July 1, 2009; 8(7): 1985 - 1994. [Abstract] [Full Text] [PDF] |
||||